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ABSTRACT
Purpose Retinoblastoma is a childhood cancer of the retina.
Clinical trials have shown that local delivery of broad spectrum
chemotherapeutic agents is efficacious. Recent studies character-
izing the genomic and epigenomic landscape of retinoblastoma
identified spleen tyrosine kinase (SYK) as a promising candidate for
targeted therapy. The purpose of this study was to conduct
preclinical testing of the SYK antagonist R406 to evaluate it as a
candidate for retinoblastoma treatment.
Methods The efficacy of the SYK antagonist R406 delivered
locally in a human orthotopic xenograft mouse model of retino-
blastoma was tested. Intraocular exposure of R406 was deter-
mined for various routes and formulations.
Results There was no evidence of efficacy for subconjunctival.
R406. Maximal vitreal concentration was 10-fold lower than the
minimal concentration required to kill retinoblastoma cells in vitro.
Dosage of R406 subconjunctivally from emulsion or sus-
pension formulations, direct intravitreal injection of the
soluble prodrug of R406 (R788), and repeated topical
administration of R406 all increased vitreal exposure, but
failed to reach the exposure required for retinoblastoma cell death
in culture.
Conclusion Taken together, these data suggest that R406 is not a
viable clinical candidate for the treatment of retinoblastoma. This
study highlights the importance of pharmacokinetic testing of
molecular targeted retinoblastoma therapeutics.
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INTRODUCTION
Retinoblastoma is the most common primary intraocular ma-
lignancy of childhood and the third most common pediatric
cancer in infants. Each year, approximately 300 cases of retino-
blastoma are diagnosed in the United States and 5,000 cases are
diagnosed worldwide (1). While mortality is low with aggressive
multimodal therapy, partial or full loss of vision occurs in ap-
proximately 50% of patients with advanced bilateral retinoblas-
toma (2). In addition, there are significant late effects of therapy
including facial malformations and increased incidence of sec-
ondary malignancies (3–5). Locally delivered targeted therapies
may maintain high cure rates while improving ocular salvage
and vision preservation and reducing late effects of therapy.
Recently, characterization of the genetic and epigenetic
landscapes of retinoblastoma revealed increases in expression
of the proto-oncogene spleen tyrosine kinase (SYK) (6).
Though not expressed in normal human retinas, SYK was
found to be upregulated in 100% (82/82) of the
retinoblastoma samples and SYK was shown to be required
for retinoblastoma cell survival (6). The preclinical candidate
SYK inhibitor BAY-61-3606 was efficacious in blocking pro-
liferation of human orthotopic retinoblastoma xenografts
in vivo (6). In this study, we focused on the SYK inhibitor
R406. The orally available prodrug of R406, fostamatinib
(R788), has advanced into late-phase clinical trials for oral
therapy of autoimmune disorders (7, 8). Fostamatinib is a
prodrug that is processed to the active form (R406) in the
intestine and previous studies have shown that R406 can
induce retinoblastoma cell death in culture (6).
We evaluated in vivo efficacy of R406 in an orthotopic
xenograft mouse model of retinoblastoma using the approach
that was previously successful for nutlin-3a and BAY-61-3606
(6, 11): 1) developing a solution formulation suitable for local
delivery using FDA-approved ophthalmic additives; 2) then
performing preclinical efficacy and pharmacokinetics studies
of subconjunctival R406 in combination with systemic
topotecan (R406oc/TPTsys), following a clinically relevant
dose and schedule. We found no evidence of efficacy for
R406 delivered using this route and formulation, so we per-
formed in vitro assays to estimate the minimal exposure re-
quired for caspase-induced retinoblastoma cell death and
in vivo pharmacokinetics studies to determine the intraocular
exposure following a subconjunctival dose of R406 in solution.
Comparing in vitro pharmacodynamic response with the in vivo
pharmacokinetic profile, we showed that vitreal exposure of
R406 following subconjunctival delivery of R788 was approx-
imately 100-fold lower than the minimal exposure required to
kill retinoblastoma cells in culture (>1 μM for at least 12 h).
Next, we performed PK studies of alternate formulations of
R406 to determine if intraocular exposure following
subconjunctival dosing could be increased. Formulation of
R406 in higher concentration emulsions or suspensions in-
creased vitreal exposure compared with solution formulation
but still did not achieve target exposure, so we expanded our
investigation to include alternative routes and prodrugs.
Intravitreal injections of aqueous soluble drugs have been
used for retinoblastoma treatment. To determine if R788 (the
more water soluble prodrug form of R406) was a candidate
for local delivery we examined conversion of R788 to R406 in
extracted murine vitreous. After demonstrating that R788 is
converted to R406 by phosphatases in the vitreous, we per-
formed pharmacokinetic studies of locally delivered R788.
Intravitreal and subconjunctival delivery of R788 failed to
achieve target doses of R406. Topical delivery of a lipophilic
R406 palmitate salt in eye drops achieved the highest intra-
ocular levels of R406 (~1-2 μM), which were sustainable via
repeated topical dosing, but exposure was still below our
designated therapeutic target.
We examined all feasible delivery routes and formulations
for the SYK inhibitor R406 and found that none achieved an
intraocular exposure needed to induce retinoblastoma cell
death. These data combined with the lack of evidence of
efficacy in a preclinical mouse model suggest that R406 is
not a viable clinical candidate for retinoblastoma. These data
on R788/R406 highlight the importance of careful drug
formulation and route selection along with comprehensive
pharmacokinetics in preclinical models before moving new
therapies into clinical trials.
MATERIALS AND METHODS
Chemicals and Materials
The internal standard OSI-906 (>99% purity, batch lot
S109103) was purchased from Selleck Chemicals (Houston,
TX). R406 phenylsulfonate salt and R788 were purchased
from Selleck Chemicals (Houston, TX, USA). LC-MS
Chromasolv grade acetonitrile (ACN) was purchased from
Fisher Scientific (Loughborough, UK). LC-MS Chromasolv
grade formic acid was obtained from Sigma-Aldrich (St.
Louis, MO). Milli-Q water as an ultrapure laboratory grade
water was used in aqueous mobile phase. Blank murine plas-
ma was obtained from Hilltop Lab Animals, Inc. (Scottdale,
PA, USA). Blank murine vitreous was harvested from a mixed
population of mice and stored at −80°C until use. All other
reagents were of analytical grade or higher. Preparation of
R406 free base and palmitate salt are described in the
Supplementary Information. For chemical structure of R406
free base, R406 phenylsulfonate salt, R406 palmitate salt and
R788, see Fig. S1.
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Formulations
For oral delivery of R788, the target dose of 25 mg/kg R788
was administered by oral gavage as a 4 mM solution in 0.01 N
citrate buffer, pH 6 (9). For subconjunctival administration,
R788 was prepared at a concentration of 4 mM in 2% PEG-
800 and filtered through a 0.22 μm filter prior to use (see
Table S1). R788 was also administered subconjunctivally as a
suspension at a concentration of 25 mM in 10% 2-
hydroxylpropyl-β-cyclodextrin (HPβCD, Sigma-Aldrich).
For subconjunctival administration, R406 phenylsulfonate
salt was administered at a concentration of 800–900 μM as
a cosolvent solution in a formulation of 5% Cremaphor-eL,
0.5% ethanol, 0.2% Tween 80 and 94.3% PBS, filtered
through a 0.22 μm filter prior to use (see Table S2). R406
phenylsulfonate salt was also administered subconjunctivally
at a dose of 31.4 mM solution in DMSO. R406 free base was
administered subconjunctivally at a concentration of 6.5 mM
as a 25% castor oil (Sigma-Aldrich) emulsion. This emulsion
was prepared by mixing castor oil: ethanol (1:1) solution of
R406 (approx. 35 mM), in vacuo evaporation of the ethanol,
and centrifugation to remove any excess R406, then emulsi-
fying the R406 oil phase in an aqueous phase comprised of
Cremaphor-eL, Tween 80 and PBS (final composition of the
emulsion: 25% castor oil, 5%Cremaphor-eL, 0.2%Tween-80,
69.8% PBS) by probe sonication. For intravitreal injection,
R788 solution was prepared by filtering a 0.12 mM (120 μM)
solution of R788 in saline through a 0.22 μm filter. R788
solution was diluted to a concentration 10-fold lower than the
compound’s maximum solubility in saline (approx. 1.2-
1.4 mM) before administration to mice to better approximate
themaximum concentration achievable in a human intravitreal
injection. For topical delivery, 25–30 mM suspensions were
prepared in 5% HPβCD. R406 or R788 concentration in all
formulations was determined by UPLC prior to study (in cases
where formulation was filtered before administration, concen-
tration was determined post-filtering) Table I.
Efficacy Testing of R406 in a Human Orthotopic
Xenograft Mouse Model of Retinoblastoma
Preclinical testing was carried out in human orthotopic xeno-
graft mice using the methods previously described (10, 11). SJ-
39 retinoblastoma cells were injected into the vitreous of 30
immunocompromised mice (J:NU, The Jackson Laboratory
(Bar Harbor, ME, USA)): 10 were untreated and 20 received
subconjunctival injections of R406 in solution formulation
(R406oc) and systemic topotecan (TPTsyst) combination ther-
apy administered over a 5-day course every third week as
follows: 10 μL R406 per eye at a concentration of 0.8 -
0.9 mmol (8–9 nanomoles/eye) on day 1, and TPTsyst
(0.7 mg/kg per dose, i.p.) on days 1 to 5 (see Fig. 1a). Mice
were scheduled to receive six courses of therapy (18 weeks
total). Before each course of therapy, mice were examined and
intraocular pressure (IOP) was read as previously de-
scribed (10, 11). If intraocular pressure was elevated
above normal (IOP>20) or eye rupture was observed,
mice were taken off study and time to event was re-
corded. At the completion of the study event-free sur-
vival (EFS) was analyzed for the R406oc/TPTsyst treated
and untreated groups.
Bioconversion of R788 to R406 in Mouse Vitreous
Conversion of R788 to R406 was examined in freshly har-
vested murine vitreous, 2 U/mL bovine alkaline phosphatase
in PBS (positive control), or plain PBS (no enzyme, negative
control) at 37°C using a modified version of previously de-
scribed phosphate prodrug conversion protocols (9, 12).
Alkaline phosphatase (ALP) from bovine intestinal mucosa
was obtained from Invitrogen and was reconstituted and
diluted according to the manufacturer’s instructions.
Vitreous was harvested from a mixed population of mice,
pooled, and kept on ice for 1 - 2 h. The incubation media
were pre-warmed to 37°C before the reaction was initiated by
addition of 1 mM of R788 in saline (6 μL of R788 in saline into
234 μL of incubation media in a 1.5 mL Eppendorf tube).
R788 was diluted into the incubation media at a 1:40 ratio
(volume:volume) to mimic the dilution encountered during
intravitreal injection in humans (typically 100 μL injection
volume into 4–5 mL of human vitreous volume (13, 14).
Initial estimated concentration of R788 was 25 μM. At the
desired time points (0, 5, 10, 20, 30, 45, 60, and 120 min) an
aliquot of 25 μl was collected from each incubation vial and
transferred to a 1.5 mL Eppendorf tube, containing
25 μl of acetonitrile to terminate the reaction. 3 sam-
ples were tested per time point. Samples were stored at
−80°C until quantification.
Animals
All procedures were approved by the St. Jude Institutional
Animal Care and Use Committee and conducted in accor-
dance with the National Institutes of Health guidelines for the
care and use of laboratory animals (15). The animal facility is
accredited by the American Association for Accreditation of
Laboratory Animal Care. For oral gavage and subconjunctival
studies, adult female C57BL/6 and B6D2F1/J mice were
purchased from The Jackson Laboratory (Bar Harbor, ME,
USA). Heterozygous female nudes approximately 11 weeks in
age were used for intravitreal injection studies. For topical
studies, adult female C57BL/6 mice were purchased from
Charles River (Wilmington, MA, USA). Mice were
housed in a temperature-controlled room on a normal 12-h
light/dark cycle, with free access to water and standard labo-
ratory food.
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PK Study Drug Administration and Sample Collection
For the systemic delivery study R788 was administered as a
single bolus dose (25mg/kg, 10mL/kg volume) by oral gavage.
For the subconjunctival administration studyR788 orR406 (10
µL of formulation) was injected into the subconjunctival space
of an anesthetized mouse using a Hamilton microliter syringe
(Hamilton company, Reno NV). For the intravitreal adminis-
tration study, R788 (5 μL of 0.15 mM in saline) was adminis-
tered to each eye via direct injection. To perform the intravit-
real injection, mice were anesthetized, a small incision between
the sclera and the cornea was created with a 13G needle, and
the R788 was injected into the vitreous using a Hamilton
microliter syringe. For the topical administration study, R406
(2 μL of 25–30 mM suspension) was applied as a drop to the
surface of each eye of an anesthetized mouse. All routes, doses
and formulations tested are summarized in Table I.
At serial time points (0.5, 1, 2, 4, and 8 h post-injection, n=
3 for each time point), blood was collected by terminal cardiac
puncture after isoflurane anesthesia. Whole-blood samples
were centrifuged immediately at 10,000×g for 5 min at 4°C
to separate plasma. Once the cardiac puncture and blood
collection was completed, the animal was perfused with
10 mL of saline and euthanized by cervical dislocation. Eyes
were removed, rinsed in PBS, gently patted dry, then rinsed
and dried again. Eyes were dissected and vitreous was collect-
ed. Plasma and vitreous samples were put on dry ice immedi-
ately after collection and stored at −80°C until analysis. For
quantitative analysis methods and assay validation methods
and results, see Supplementary Information.
PK Data Analysis
Plasma and vitreous concentration time data were analyzed
using non-compartmental analysis in WinNonlin 6.2
(Pharsight, Mountain View, CA), providing PK parameters
including Cmax (maximum observed concentration), Tmax (time
to reach maximum observed concentration), AUC (area under
the concentration time curve) andMRT (mean residence time).
AUC and AUMC (area under the concentration time first
moment curve) values were estimated with the linear trapezoi-
dal method, with parameters calculated using mean concen-
tration values at each time point. To obtain the mean concen-
trations at time points with data below the lower limit of
quantitation (BLOQ), BLOQ observations were replaced with
a value of ½ the lower limit of quantitation (LLOQ) if≥2/3rds
of the observed concentrations were above the LLOQ; other-
wise, the mean concentration was treated as missing.
RESULTS
Preclinical Testing of R406 in Mouse Models
of Retinoblastoma
Previous studies have shown that R406 and BAY61-3606 can
induce caspase-mediated cell death of retinoblastoma cells
in vitro (6). In vivo administration of BAY61-3606 showed efficacy
in human orthotopic xenografts models (6) but R406 was not
tested in vivo in that previous study. Since R406 is the SYK
inhibitor farthest along in clinical development (Phase 3), and
therefore the most likely compound to be tested clinically
against retinoblastoma, we decided to focus upon its evaluation.
In order to test the efficacy of R406 in vivo, we developed a
solution formulation using FDA approved adjuvants for oph-
thalmic applications (11). The maximum concentration of
R406 in solution was approximately 900 μM and R406 was
chemically stable in formulation for 48 h at room temperature
(Table S3 and Fig. S2). Next, we performed in vivo efficacy
studies using the solution formulation of R406 in combination
Table 1 Formulation, administration route and dosing summary for all in vivo pharmacokinetic studies
Compound Administration Route Formulation Dose Total Dose Per
Eye (nmol)
R788 (Fostamatinib disodium) Oral Solution in citric acid buffer 25 mg/kg N/A
Subconjunctival Co-solvent Solution: 2% PEG in PBS 10 μL of 4 mM per eye 40
Subconjunctival Suspension: 10% cyclodextrin in PBS 10 μL of 25 mM per eye 250
Intravitreal Saline 5 μL of 120 μM per eye 0.6
R406 phenyl-sulfonate salt Subconjunctival Co-solvent Solution: 5% Cremaphor-eL,
0.5% ethanol, 0.2% Tween 80 in PBS
10 μL of 800–900 μM per eye 8−9
Subconjunctival DMSO 10 μL of 31.4 mM per eye 314
R406 free base Subconjunctival Emulsion: 25–30% castor oil, 5%
Cremaphor-eL, 0.2% Tween-80 in PBS
10 μL of 6.5 mM per eye 65
Topical Suspension: 5% HPβCD in PBS 2 μL of 25 mM 50
R406 palmitate salt Topical Suspension: 5% HPβCD in PBS 2 μL of 25 mM 50
Topical Suspension: 5% HPβCD in PBS 2 μL of 40 mM, administered hourly
1, 2, 3 or 4 times
80, 160, 240
or 320
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with systemic topotecan (standard for our preclinical evaluation
of new retinoblastoma agents (11) following a clinically relevant
dose and schedule as was previously done for nutlin-3a and
BAY-61-3606 (6, 11). SJ-39 retinoblastoma cells were injected
into the vitreous of 30 immunocompromised mice and animals
were randomized into two treatment groups: 20 received
subconjunctival injections of R406 in solution formulation
(R406oc) and systemic topotecan (TPTsyst) combination therapy
administered over a 5-day course every third week (see Fig. 1a)
and 10 were untreated. Animals were scheduled to receive 6
courses of treatment (18 weeks total), but no animal completed
the entire 6 courses. All animals were taken off study by 63 days
due to elevated intraocular pressure (IOP>20) or eye rupture.
Event free survival (EFS) was analyzed for the two groups
(Fig. 1b). Log-rank test showed that there was a statistically
significant difference in the distribution of time to event be-
tween the two groups (p=0.005), and the treated group had a
longer EFS than the untreated group. The proportion of event
free survivals at 21 days were 50% and 90% for the untreated
and treated group, respectively; at 42 days the EFS proportions
were 0% and 30% for the untreated and treated group, re-
spectively. Median event free survivals were 32.5 days and
42 days for untreated and treated group, respectively. This is
very similar to our historical studies with TPTsyst alone.
Though there is a slight improvement in outcome for
the R406oc/TPTsyst treated group, no animals survived
beyond 63 day, suggesting R406 delivered with this
route and formulation does not substantially delay disease
progression.
Pharmacokinetics of Subconjunctival R406 Ocular Solution
in Mice
To determine if the lack of evidence of efficacy of
subconjunctival R406 in a solution formulation was due to
suboptimal ocular exposure, we performed a pharmacokinetic
experiment. Briefly, 10 μl of R406 solution formulation was
delivered to each eye of 15 mice and the plasma and vitreous
were harvested at different time points (0.5, 1, 2, 4, and 8 h).
The concentration of R406 was measured at each time point
in each tissue and the concentration of drug was plotted as a
function of time (Fig. 2). The 4 h and 8 h data are not shown,
as the majority of R406 concentrations in these samples were
BLOQ. These data show that systemic exposure (plasma) was
Fig. 1 In a human orthoptopic
xenograft preclinical mouse model
of retinoblastoma subconjunctival
R406 does not improve provide
efficacy. (a) Chemotherapy
schedule for 1 course of therapy.
Animals were scheduled to
complete 6 courses of therapy
(18 weeks). (b) Kaplan Meier plot of
event free survival (EFS) of
orthoptopic xenograft mice over
time (event defined here as
elevated intraocular pressure
(IOP>20) or eye rupture). One
group received subconjunctival
R406 in a solution formulation
(10 μL per eye of approx.
800–900 μMR406 phenylsulfonate
salt per dose) in combination
with systemic topotecan (TPT)
(0.7 mg/kg per dose, i.p.) (n=20)
and another group was untreated
(n=10). No animals in either group
completed the entire 6 courses of
treatment; all animals were taken off
study by 63 day.
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low following subconjunctival delivery of R406 as expected
(Fig. 2). However, exposure of R406 in the vitreous failed to
reach pharmacologically significant thresholds (Fig. 2).
Importantly, the maximal concentration achieved (0.05 μM)
was well below the concentration required to kill the most
sensitive retinoblastoma cell line (RB355 in culture, Fig. S3).
RB355 cells in culture were treated with DMSO, 1, 2.5, or
5 μM of R406 for varied exposure durations (0, 6, 12, 24, 48
and 72 h). For the cells in the 2.5 and 5 μM treatment groups,
the proportion of activated caspase 3+ cells measured by
immunostaining increased with increasing exposure duration.
Incorporation of 5-ethynyl-2′-deoxyuridine (EdU) was used to
detect DNA synthesis. The proportion of cells that incorpo-
rated EdU in the 5 μM treatment groups decreased with
increasing exposure time (Fig. 3e). In contrast, cells treated
with 1 μM R406 did not show any increase in caspase 3+
activation compared to untreated cells or cells treated with
DMSO for any exposure time tested up to 48 h (Fig. 3f to j).
Viability of RB355 cells in culture is reduced to 50% of the
viability of DMSO treated cells when exposed to 2.5 μM
R406 for an exposure duration between 24 and 48 h or
5 μM R406 for an exposure duration between 12 and 24 h.
There is no reduction in viability compared to DMSO treated
controls for RB355 cells in culture treated with 1 μMR406 for
up to 24 h exposure, and at longer exposure durations (48 –
72 h), viability only drops by approximately 20% (Fig. S3).
Comparing the in vivo pharmacokinetics (Fig. 2) and in vitro
pharmacodynamics data (Fig. 3, Fig. S3) suggests that the lack
of evidence of efficacy observed in the preclinical study
(Fig. 1b) was due to insufficient intraocular exposure of
R406 from the solution formulation.
Pharmacokinetics of R406 Emulsion, Suspension, and Drops
In order to increase the concentration of R406 delivered to
the eye from subconjunctival injection, we developed an
emulsion formulation using castor oil and other FDA ap-
proved adjuvants for ophthalmic emulsions (11). Using this
approach, we achieved a concentration of 6.5 mM of R406 in
emulsion and the emulsion was stable for 48 h at room
temperature (Fig. S10, Tables S12 and S13). This provided
a formulation with 7-fold increased R406 concentration com-
pared to the solution formulation. We performed a pharma-
cokinetic experiment after delivery of 10 μl of R406 emulsion
as described above for the R406 solution (Fig. 4a). As a
control, we used a high concentration (31.4 mM) of R406 in
DMSO. While it is not clinically feasible to deliver R406 in
DMSO and DMSO might disrupt biological membranes
causing an overestimate of vitreous exposure, it provides a
useful benchmark for peak concentration of R406 achievable
from subconjunctival delivery (Fig. 4b). The R406 emulsion
and R406 in DMSO both led to a significant increase in
maximal vitreal concentration and overall exposure but nei-
ther reached the targeted efficacious exposure (Fig. 4a and b,
Table II). Subconjunctival R406 suspension was not evaluat-
ed, as the DMSO control indicated the maximum intraocular
concentration that could be reached for R406 from this route
was approximately 1 μM.
Previous work has shown that ocular absorption of a drug
via the topical route (drops applied to the cornea) can be
enhanced by increasing its lipophilicity (16). To evaluate the
topical route for R406 delivery, we tested the intraocular
concentration after a single topical dose of R406 free base or
an R406 palmitate salt. R406 levels in the eye were 0.1±
0.06 μM at 0.5 h and 0.1±0.1 μM at 1 h post dosing with
R406 free base drops, and 0.3±0.3 μM at 0.5 h and 0.3±
0.2 μM 1 h post dosing with R406 palmitate salt drops. The
R406 palmitate salt achieved higher intraocular concentra-
tions than the R406 free base, but the difference between
average intraocular concentration at both time points was
not statistically significant (t-test, p-value for 0.5 h=0.3, p-
value for 1 h=0.2). No detectable drug was present in the
plasma samples (data not shown). The advantage of ocular
drops is that repeat daily dosing can be readily achieved. To
determine if repeated dosing of the R406 palmitate salt drops
could increase intraocular exposure, we dosed mice up to four
times with a 40 mM R406 palmitate 5% cyclodextrin suspen-
sion and measured the vitreal concentration of R406 at 0.5, 1,
and 2 h after the last of 1, 2, 3, or 4 hourly doses (Fig. 5).While
exhibiting high variability (coefficient of variation (CV)>40%
at nearly all observations), mean intraocular concentration-
time profiles during the period of time 0.5 to 2 h post-dosing
Fig. 2 Pharmacokinetic behavior of R406 administered as in the efficacy
study. Concentration of R406 measured at 0.5, 1.0, 2.0, and 4.0 h in the
plasma (dashed line, empty circles) and vitreous (solid line, filled circles)
following subconjunctival delivery of R406 salt in cosolvent solution (10 μL
per eye of 880 μM R406 phenylsulfonate salt).
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were similar for repeated doses, with some increase in the
mean value at the 1 h post dosing time point for 3 or 4
doses compared with 1 or 2 doses. A vitreous concen-
tration of ~1-2 μM is sustained for 1.5 h after each
application of eye drops, demonstrating that R406 con-
centrations above 1 μM could be sustained using the topical
route. However the maximal concentration achieved is still
below the targeted concentration.
Intravitreal Injection of R788
Previously, dexamethasone phosphate prodrugs have been
successfully administered as subconjunctival injections,
resulting in high concentrations of dexamethasone in the
vitreous (17, 18). This suggests phosphatases are present in
ocular tissues, but phosphatase activity in extracted vitreous
has not been characterized. To determine if R788 can be
converted to R406 in the mouse eye, we incubated fresh
murine vitreous with R788 and measured the accumulation
of R406 over time (Fig. 6a). As a negative control, we used
PBS; as a positive control, we used PBS with alkaline phos-
phatase (ALP) (2 U/mL concentration). R788 was converted
to R406 (100% conversion within 2 h) in extracted mouse
vitreous suggesting that the prodrug can be effectively deliv-
ered directly to the eye. High variability in concentration and
apparent concentration decrease at later time points in the
Fig. 3 Cellular pharmacodynamic study defining target time concentration curve RB355 cells in culture are exposed to DMSO, 1, 2.5 and 5 μM R406 for 0, 6,
12, 24, 48, or 72 h. (a to e) EdU staining of RB355 cells treated with 0 (DMSO), 1, 2.5, or 5 μM R406 for 0, 6, 12, 24, 48, or 72 h. (f to j) Caspase staining of
RB355 cells treated with 0 (DMSO), 1, 2.5 or 5 μM R406 for 0, 6, 12, 24, 48, or 72 h.
Fig. 4 Pharmacokinetics of R406 following subconjunctival administration. Concentration of R406 measured at 0.5, 1.0, 2.0, and 4.0 h in the plasma (dashed
line, empty circles) and vitreous (solid line, filled circles) following (a) subconjunctival delivery of R406 free base in a 25–30% castor oil emulsion (10 μL per eye of
6.5 mM R406 free base). (b) subconjunctival delivery of R406 in DMSO (10 μL per eye of 31.4 mM R406 phenylsulfonate salt). Neither formulation achieves the
target drug concentration in the eye.
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ALP positive control samples (Fig. 6a) may be related to
R406’s solubility limitations.
There are now several examples of direct injection of
chemotherapy or biological agents into the vitreous for the
treatment of retinoblastoma in patients (19–21). Direct intra-
ocular administration of R788 provides maximal R406 con-
centration of 1 μM at 0.5 h post dosing (Fig. 6b, the earliest
time point measured). Systemic exposure is lower following
intravitreal injection, but the vitreous concentration-time
curve is similar to that following subconjunctival injection of
R788 in solution formulation (Fig. 7b). Oral delivery of R788
and subconjunctival injection of R788 in suspension show no
improvement in overall exposure compared to intravitreal
injection of R788 (Fig. 7a and c).
DISCUSSION
Local Delivery of Molecular Targeted Therapy
for Retinoblastoma
Due to the unique physiology of the eye, numerous routes of
delivery are available. Systemic routes can be used for ocular
therapeutics, but are typically limited by the Blood Retinal
Barrier (BRB), which drives up doses needed to reach effica-
cious concentrations, thus causing increased systemic toxicity
(22–24). Therefore local delivery, which can drastically reduce
systemic exposure while simultaneously increasing ocular ex-
posure, is an attractive option.
Local ocular delivery routes generally fall into four catego-
ries: topical (transcorneal), periocular (transcleral), intravitreal
(direct injection), and intra-arterial infusion (21, 25, 26).
Though multiple delivery routes are available for retinoblas-
toma therapeutics, all routes are not amenable to all com-
pounds. Some chemotherapy drugs like topotecan effectively
cross the BRB, with equivalent intraocular PK profiles from
either systemic or local topotecan delivery (10, 27). In contrast,
carboplatin (28–30) and nutlin-3a (11, 31) cannot be admin-
istered systemically due to insufficient penetration across the
BRB and in these cases subconjunctival injection has been
Fig. 5 Pharmacokinetics of R406 following topical administration. Intraocular
R406 concentration measured at 0.5, 1, and 2 h post dosing with one, two,
three, or four topical administrations of R406 palmitate salt in suspension (2μL
per eye of 40 mM R406 palmitate salt in 5% HPβCD per dose). Vitreous
collected 0.5, 1, and 2 h after the latest dose. N=3-5. Error bars represent
standard deviations (where error bars are not shown they fall into
background).
Fig. 6 Pharmacokinetics of R406 following intravitreal administration of R788. (a) Bioconversion of R788 to R406 in freshly harvested, pooled murine vitreous
(filled circles), PBS alone (empty circles), and PBS with 2U/mL alkaline phosphate enzyme (ALP) (triangles). N=3 samples per incubation media. Error bars
represent standard deviations (where error bars are not shown they fall into background). (b) Concentration of R406 measured at 0.5, 1.0, 2.0, and 4.0 h in the
vitreous (blue, squares) following intravitreal injection of R788 in saline (5 μL per eye of 120 μMR788). R406 levels BLOQ in all plasma samples. Administration of
maximal dose of R788 fails to provide target concentrations of R406 for sufficient duration.
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significantly more effective. This contrast highlights the im-
portance of utilizing PK to direct delivery route selection for
ocular therapeutics.
We examined all feasible routes of delivery to the eye includ-
ing oral administration of R788 (the conventional route of
administration in clinical RA trials), subconjunctival delivery
of R406, and topical delivery of R406 and a more lipophilic
R406-palmitate salt. Bioconversion of R788 to R406 in pooled
extractedmurine vitreous supported testing local administration
of the phosphate prodrug, so subconjunctival administration of
R788 and intravitreal injection of R788 was also evaluated.
To achieve efficacy as a retinoblastoma therapeutic, R406
must reach therapeutically effective intraocular exposure. In
preclinical mouse models of retinoblastoma, subconjunctival
R406 did not result in evidence of efficacy, and our studies
suggest this can be attributed to insufficient intraocular expo-
sure. Though local administration routes improved intraocu-
lar exposure relative to systemic delivery (Fig. 6), none of the
subconjunctival or intravitreal formulations tested provided a
vitreous Cmax above 1 μM, which our in vitro studies suggest
would be required to drive efficacy even at prolonged expo-
sure times (i.e., up to 72 h) (Fig. 3). Only topical delivery of the
R406 palmitate salt in cyclodextrin drops provided a vitreous
Cmax above 1 μM, which can be sustained via repeated dosing.
The topical route achieved higher intraocular concentrations
of R406 than any other route tested and has the advantages of
non-invasiveness and ease of administration of repeated doses.
No chemotherapy drugs are currently administered topically,
but these results highlight the need for further exploration of
this route for retinoblastoma therapeutics.
Fig. 7 Pharmacokinetics of R406 following administration of R788 by several routes. Concentration of R406 measured at 0.5, 1.0, 2.0, and 4.0 h in plasma
(dashed line, empty circles) and vitreous (solid line, filled circles) following (a) oral delivery of R788 (25 mg/kg R788 in citric acid buffer) (b) subconjunctival delivery
of R788 cosolvent solution (10 μL per eye of 4 mM R788). (c) subconjunctival delivery of R788 suspension (10 μL per eye of 25 mM R788). No route achieves
the targeted drug exposure.
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R406 Ocular Pharmacokinetics
Our results suggest that the primary drivers of ocular PK for
R406 are (1) aqueous solubility (2) lipophilicity and (3) dissolu-
tion behavior. In PBS, the maximum solubility of R788 is
1.4 mM, the maximum solubility of the R406 phenylsulfonate
salt is 0.4 μMandR406 free base is insoluble (below the limit of
quantitation). Lipophilicity of the compounds tested follows the
order (least lipophilic to most): R788<R406 phenylsulfonate
salt<R406 free base, while aqueous solubility follows the order
(lowest solubility to highest): R406 free base<R406
phenylsulfonate salt<R788. At similar total doses, the more
water soluble prodrug R788 in cosolvent solution (40 nmol
total dose per eye) achieves a maximum vitreous concentration
6-fold higher than the water insoluble R406 free base in emul-
sion (65 nmol total dose per eye) (Figs. 6b and 3a, Table II),
which suggests aqueous solubility may control maximal equi-
librium ocular drug concentrations. R406 administered at a
high dose in DMSO achieves a comparable vitreous Cmax to
R788 cosolvent formulation (Figs. 3b and 6b, Table II), sug-
gesting that the upper limit of compound solubility in vitreous is
driven by solubility of the converted R406. A 6.25-fold increase
in dose of locally administered R788 does not increase vitreous
Cmax or vitreous exposure, but dramatically increases systemic
exposure (Table II). This suggests rapid clearance occurs once
the maximum vitreous concentration is reached, and that
increasing the amount of drug administered to the
subconjunctival space will not increase vitreous Cmax beyond
this limit. When comparable total doses of R788 and R406 salt
are administered locally (250 and 314 nmol total per eye,
respectively), the R406 salt increases vitreous exposure and
decreases plasma exposure, achieving a ratio of vitreous AUC
to plasma AUC 22-fold higher than the more water-soluble
R788 in suspension (Table II). This suggests that when local
dose is sufficient, R406 phenylsulfonate salt exhibits greater
retention at the injection site due to its limited water solubility,
while themore water soluble prodrug diffuses more readily from
the injection site into systemic circulation. R406 phenylsulfonate
salt and R788 have very similar molecular weights (628.6 and
624.4, respectively), suggesting that their differences in lipophi-
licity, solubility and dissolution are driving PK.
Ocular mean residence times (from shortest to longest) were
as follows: R788 systemic/oral≈R406 salt local solution<R788
local solution (all less than 1 h)<R788 local suspension<R406
salt local DMSO<R406 base local emulsion (Table II). The
emulsion and the R406 salt in DMSO exhibit the longest mean
residence times (MRT≥2 h). The R406 emulsion may form a
drug depot in the subconjunctival space, analogous to the use of
intramuscular injections of oil carriers and suspensions in de-
livery of long acting injectable (LAI) antipsychotics where slow
diffusion of the drug ester out of the oil phase and into the blood
stream prolongs the maintenance of therapeutic drug
concentrations (32). When added to buffer, R406 salt in
DMSO precipitates out of solution (see Supplement). The
solution of R406 salt in DMSO may therefore be functionally
comparable to the long-acting injectable formulation of
olanzapine, which is injected into the gluteal muscle as a
suspension of micron sized crystals of olanzapine and pamoic
acid in aqueous solution, providing sustained release (2–4
weeks) as the salt gradually dissolves and diffuses into systemic
circulation (33). If R406 salt precipitates out of DMSO in the
subconjunctival space, depot formation will lead to re-
dissolution of the R406 precipitate sustaining release into the
eye and limiting rapid clearance from the injection site. This
interpretation is consistent with the rapid clearance and high
systemic exposure observed when a relatively high concentra-
tion of R788 in suspension is administered locally.
In the case of subconjunctival delivery of R406, increasing
compound lipophilicity improves the ratio of vitreous AUC to
plasma AUC, but an increase in drug lipophilicity may not
improve ocular PK overall if there is a trade-off in aqueous
solubility: the most lipophilic of the compounds tested (R406
free base), reaches relatively low intraocular concentrations
compared with other local formulations, while the least lipo-
philic (R788) has the shortest MRT. Compare these results to
the previous success with local delivery of nutlin-3a (AUC
ratio of vitreous to plasma for subconjunctival administra-
tion=28.6), which has a water solubility of approximately
40 μM (100-fold higher than R406 phenylsulfonate salt) and
a higher logP than any of the compounds tested in this study.
Our current understanding of subconjunctival administration
suggests that successful delivery depends on optimizing a
three-way balance between aqueous solubility, lipophilicity,
and dissolution because these properties impact absorption
across barriers, tissue partition, maximum concentration
achievable in vitreous, retention at the injection site, and ratio
of compound diffusing out systemically relative to the amount
absorbed into the eye. Because inverse relationships may exist
amongst solubility, lipophilicity, and dissolution, it is unlikely
that any one of those properties can be optimized individually;
improvements in one property will need to be weighed against
potential trade-offs in another.
Targeting SYK/BCL2 in Retinoblastoma
Despite the failing of R406 as a retinoblastoma clinical can-
didate, SYK remains a promising target as there are many
other small molecule SYK inhibitors with diverse physio-
chemical properties to evaluate as retinoblastoma therapeutics
(34–38). Previous studies of SYK inhibition have implicated a
number of downstream signalingmolecules, including the Bcl-
2 family of proteins as mediators of the SYK survival signal
(35, 39). This suggests that some of the small molecule Bcl-2
inhibitors currently being developed for other cancer, such as
obatoclax and TW-37 (40) may also prove to be effective
therapeutic agents in retinoblastoma.
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Conclusion
The SYK inhibitor R406, currently in clinical development
for rheumatoid arthritis, can induce caspase-mediated cell
death of retinoblastoma cells in culture. Subconjunctival
administration of R406 failed to provide any evidence of
improvement in tumor response in preclinical models of
retinoblastoma. We found that vitreal exposure following
subconjunctival delivery of the R406 solution formulation
was below the exposure required to induce caspase-
mediated cell death of retinoblastoma cells in culture. We
developed emulsion and suspension formulations of R406,
which increased the vitreal exposure of R406, but still failed
to reach the target exposure. The R788 prodrug was effi-
ciently converted to R406 in extracted vitreous and in vivo,
but following direct intravitreal injection of R788, R406
exposure was still insufficient. Topical delivery of R406-
palmitate achieved intraocular concentrations above 1 μM,
which was sustainable via repeated dosing. Though local
delivery via the subconjunctival, topical and intravitreal
routes improved vitreous exposure compared with oral de-
livery, vitreous exposure from all routes and formulations
tested was not within the range required to kill retinoblas-
toma cells in culture. Therefore, the preclinical models
strongly suggest that R406 is not a viable clinical candidate
for retinoblastoma. Future efforts may focus on combining
R406 with other agents, testing other SYK inhibitors with
different physiochemical properties that may improve intra-
ocular pharmacokinetics, or targeting other proteins in the
pathway.
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